Skye Bioscience’s nimacimab blocks CB1, the same receptor targeted by an obesity drug candidate now in the hands of Novo Nordisk. But Skye contends its Phase 2-ready antibody drug has several advantages over the small molecule that joined Novo’s pipeline in a deal valued at $1 billion.

The post Skye Bioscience Falls Short in Glaucoma Trial, But It’s Full Steam Ahead for Obesity Program appeared first on MedCity News.

Novo Nordisk’s focus on diabetes and obesity shape its business development work, but the company is also exploring other areas. Top Novo Nordisk M&A executive John McDonald discussed his company’s strategy during a session at the BIO conference in San Diego.

The post At BIO, Novo Nordisk’s Top Dealmaker Talks M&A Strategy and What’s Next After GLP-1s appeared first on MedCity News.

GLP-1 agonists are transforming the weight loss market. Experts weighed in on the changes they’re seeing, speaking in a panel discussion during the MedCity News INVEST Conference in Chicago.

The post Navigating Opportunities and Challenges in the GLP-1 Drug Gold Rush appeared first on MedCity News.

Amgen is confident its injectable obesity drug would have a differentiated profile compared to medications now on the market from Novo Nordisk and Eli Lilly and it’s now preparing for Phase 3 testing. But an oral obesity drug in Amgen’s pipeline will not advance beyond Phase 1.

The post Amgen Puts Its Weight Behind Obesity Drug With Potential Edge Over Lilly, Novo Nordisk Meds appeared first on MedCity News.

How targeted outreach and heightened engagement can help companies achieve better outcomes

The post Breaking Down Barriers to Obesity Care appeared first on MedCity News.

Obesity/overweight is a significant causal factor in chronic illness and cancer. Weight loss can help people with obesity/overweight avoid and/or manage chronic illness. GLP-1s cause weight loss. So, are GLP-1s the answer to America’s obesity and chronic illness crises? Not if we overlook a key problem at the heart of both challenges: lack of access to nutritious food in the land of plenty.

The post GLP-1s Alone Are Not the Answer to America’s Obesity and Chronic Illness Crises appeared first on MedCity News.

In a webinar last week, BuildMyHealth CEO and Co-founder Dr. Jonathan Kaplan shared how physician practices not only can access the weight loss drug by working with compounding pharmacies, but also use BuildMyHealth to provide this drug to their own patients who are suitable candidates for the drug.

The post Build My Health Webinar Highlights New Age for Physician Practices with Rise of GLP1 Drugs for Obesity appeared first on MedCity News.

By eliminating the term “obesity” in favor of person-centric language, we pave the way for a more equitable healthcare system that prioritizes the well-being of all individuals, regardless of their size or shape.

The post Let’s Make This the Last World Obesity Care Week appeared first on MedCity News.

Novo Nordisk reported its weight loss pill amycretin led to greater weight loss measured at 12 weeks compared to clinical trial results for its blockbuster obesity drug Wegovy. But these results are from a small Phase 1 study and more testing is needed.

The post Novo Nordisk Obesity Pill Flashes the Potential to Beat Wegovy in Weight Loss appeared first on MedCity News.

Kellogg CEO Gary Pilnick recently encouraged families struggling to put food on the table to turn to cereal as their go-to dinner option. Food-as-medicine executives are none too thrilled about his comments — they argue that the remarks underscore the dire need to increase public education about affordable, healthy meal planning.

The post How Food-as-Medicine Execs Are Responding to Kellogg CEO’s ‘Let Them Eat Flakes’ Remarks appeared first on MedCity News.

In this episode, the CEO of Lumen talks about the sleek consumer device and why he is at a b-to-b healthcare conference.

The post MedCity Pivot Podcast: A Conversation with Lumen CEO Daniel Tal Mor appeared first on MedCity News.

The weight loss achieved by Viking Therapeutics’ obesity drug tops results posted by Eli Lilly’s Zepbound in its pivotal test. But Viking still needs to show its results can hold up in a larger Phase 3 clinical trial.

The post Viking Therapeutics Obesity Drug’s Data Raise Best-in-Class Expectations appeared first on MedCity News.

In preclinical testing, combining BioAge Labs’ experimental drug with Eli Lilly weight drug Zepbound led to greater weight loss compared with Zepbound alone. Now the company plans to run a Phase 2 study to see if it can replicate those results in humans.

The post Lose Fat, Not Muscle: Next Test for Lilly’s Zepbound Pairs It With BioAge Drug appeared first on MedCity News.

Omada’s newly expanded GLP-1 Care Track provides tailored exercise plans, support for getting off of GLP-1s and calorie tracking. It also offers insight into who is responding to GLP-1s and who is engaging in Omada’s program.

The post Omada Expands GLP-1 Care Track To Include Exercise Plans, Member Level Reporting appeared first on MedCity News.

After Novo Holdings acquires Catalent, it will sell three of the contract manufacturing giant’s sites to Novo Nordisk. Those facilities already make Novo Nordisk’s GLP-1 drugs for metabolic conditions, and they will help the company meet projected demand for these products in years to come.

The post Novo Holdings Bolsters GLP-1 Production Capacity With $16.5B Catalent Buyout appeared first on MedCity News.

Fractyl Health will use the IPO proceeds for pivotal testing of a medical device and surgical procedure intended to address root causes of diabetes and obesity. The Fractyl pipeline also includes a gene therapy for these conditions.

The post Metabolic Disorder-Focused Fractyl Health ‘GUTS’ Out a $110 Million IPO appeared first on MedCity News.

We and our collective organizations’ providers have treated 10,000’s of Americans, who suffer from obesity and/or Type 2 diabetes with GLP-1 drugs. And we believe we have important observations to share.

The post We’ve Actually Treated Tens of Thousands of People on Ozempic to Date – Here’s What Really Happens and What It Likely Means for Solving Our Obesity Epidemic appeared first on MedCity News.

GLP-1s continue to be in high demand, and the healthcare industry is watching closely to see how payers decide to cover the drugs going forward. During a virtual panel, payer executives noted that it’s important to remember that GLP-1s won’t be able to solve the country’s obesity crisis by themselves.

The post How Are Payers Approaching Obesity Management? appeared first on MedCity News.

How we discuss overweight and obese diagnoses and how we treat those patients is slowly starting to improve. However, there’s still a lot of work to be done – in how we manufacture, market, and manage life-changing weight care medications, as well as how we expand access and improve adherence to them.

The post The Prohibitive Economics of Weight Care appeared first on MedCity News.

New research found that there are no racial disparities in weight loss results among patients taking obesity drugs. However, the study found that people of color have less access to services like behavioral care or surgical interventions, which are often needed in order for patients to lose weight and keep it off. To tackle this issue, Enara Health CEO Rami Bailony argued that the U.S. healthcare system must innovate the way it dispenses weight loss drugs, employing a more holistic care approach.

The post Why One CEO Thinks Drugs Won’t Be Able to Solve the Obesity Crisis appeared first on MedCity News.

Knownwell’s $20 million Series A funding round was led by A16Z and included participation from Flare Capital Partners. The company also launched an adolescent metabolic health program.

The post Knownwell Secures $20M for Weight-Inclusive Primary Care appeared first on MedCity News.

In a new partnership, patients in need of weight loss support can receive primary care, mental health and chronic condition management through Hello Alpha. In between Hello Alpha visits, patients can access health coaching services from TrestleTree.

The post Hello Alpha, TrestleTree Partner To Support Weight Loss appeared first on MedCity News.

WeightWatchers’ new GLP-1 program offers daily nutritional and activity targets, recommended foods, recipes, food and activity tracking, a digital community, virtual workshops and access to coaches 24/7. 

The post WeightWatchers Launches New GLP-1 Support Program appeared first on MedCity News.

Twin Health raked in $50 million in Series D financing. The startup seeks to help patients improve their metabolic health and reduce the need for medications through the “digital twin” technology it sells to employers and health plans.

The post Twin Health Snags $50M to Help Employers, Health Plans Treat Metabolic Disease appeared first on MedCity News.

Prescriptions for GLP-1s are soaring, but fewer than a third of people prescribed the costly drugs will continue taking them one year later without personalized support. Without the expert guidance of a registered dietitian, you risk not achieving the significant clinical benefits these drugs offer and forfeiting the potential for sustainable, transformative health outcomes.

The post Are Registered Dietitians the Key To Optimizing Weight Loss With GLP-1s? appeared first on MedCity News.

Hims & Hers unveiled a new weight loss program on Monday that includes access to medications, educational content and digital tracking tools.

The post Hims & Hers Gets Into Weight Loss Treatment appeared first on MedCity News.

A new guide from Northeast Business Group on Health helps employers understand the challenges women face when it comes to cardiovascular disease, diabetes and obesity. It also recommends actions that employers can take to support women in their workforce.

The post NEBGH Helps Employers Combat Cardiovascular Disease in Women Through New Guide appeared first on MedCity News.

Roche’s Carmot Therapeutics acquisition brings three clinical-stage assets that the companies say could be best-in-class drugs for metabolic disorders. In addition to standalone use, Roche sees the Carmot molecules as part of potential combinations with its own drug candidates.

The post Roche Lines Up $2.7B Acquisition to Join Chase for New Diabetes, Obesity Drugs appeared first on MedCity News.

Carmot Therapeutics isn’t the first company targeting both the GLP-1 and GIP receptors to treat metabolic diseases. But the company contends that biased signaling—activating certain pathways but not others—is key to setting its drugs apart from others in the same class.

The post Carmot’s IPO Filing Makes Case for Bias in Drugging Key Obesity, Diabetes Targets appeared first on MedCity News.

The German manufacturing site is the latest capital infrastructure move for Eli Lilly, which has already made $11 billion in investments in its global manufacturing capabilities in the past three years. The new site will help Lilly meet strong demand for its diabetes and obesity drugs.

The post Eli Lilly Plans New $2.5B Manufacturing Site in Germany for Injectable Meds appeared first on MedCity News.